Status:
COMPLETED
Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies
Lead Sponsor:
Hospital General de Niños Pedro de Elizalde
Conditions:
Uric Acid Nephropathy
Eligibility:
All Genders
3-12 years
Phase:
PHASE4
Brief Summary
The aim of this study is to assess the serum uric-acid lowering effect of losartan in children with proteinuric nephropathies. Patients already treated with enalapril will be randomized to receive los...
Detailed Description
The working hypothesis is that the administration to losartan reduces significantly the serum uric acid levels in normotensive children with proteinuric nephropathies. The study will consist in a sing...
Eligibility Criteria
Inclusion
- Children with poteinuric nephropathies already treated with enalapril under our care.
- Age between 3 and 12 years.
- Normal blood pressure.
Exclusion
- Patients with high blood pressure.
- Post menarche female patients.
- Patients with hypouricemia (\< 2 mg/dL).
- Patients treated with diuretics.
- Patients with absolute or relative contraindications to receive RAAS antagonists (glomerular filtration \< 30 ml/min/1,73 m2, serum potassium \> 5,5 mEq/L).
- Patients with active rheumatic diseases.
- Patients treated with dual blockade of the RAAS (enalapril +losartan).
- Patients treated with calcineurin inhibitors.
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05402397
Start Date
July 1 2022
End Date
January 1 2024
Last Update
September 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
HGNPE
CABA, Buenos Aires F.D., Argentina, 1417